U.S. markets closed
  • S&P Futures

    3,841.75
    +7.75 (+0.20%)
     
  • Dow Futures

    30,978.00
    +42.00 (+0.14%)
     
  • Nasdaq Futures

    11,847.50
    +39.00 (+0.33%)
     
  • Russell 2000 Futures

    1,743.40
    +1.70 (+0.10%)
     
  • Crude Oil

    101.11
    +1.61 (+1.62%)
     
  • Gold

    1,769.60
    +5.70 (+0.32%)
     
  • Silver

    19.04
    -0.01 (-0.06%)
     
  • EUR/USD

    1.0264
    -0.0006 (-0.06%)
     
  • 10-Yr Bond

    2.8090
    -0.0800 (-2.77%)
     
  • Vix

    27.54
    +0.01 (+0.04%)
     
  • GBP/USD

    1.1962
    +0.0010 (+0.08%)
     
  • USD/JPY

    135.1570
    -0.6850 (-0.50%)
     
  • BTC-USD

    20,202.14
    -72.83 (-0.36%)
     
  • CMC Crypto 200

    437.17
    -2.85 (-0.65%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,256.13
    -167.34 (-0.63%)
     

Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NASHVILLE, Tenn., April 20, 2022--(BUSINESS WIRE)--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.

Conference Call Details:

Date:

Thursday, May 5, 2022

Time:

4:45 p.m. Eastern time

Participant Dial-in:

1-833-953-2434 (U.S.)
1-412-317-5763 (International)

Replay Dial-in (Passcode 9985794):
(telephonic replay through May 12, 2022)

1-877-344-7529 (U.S.)
1-412-317-0088 (International)

Webcast: (online replay through August 5, 2022)

harrowinc.com

About Harrow Health

Harrow Health, Inc. (Nasdaq: HROW) is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic vision care. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005352/en/

Contacts

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737